Casdin Capital is a New York-based research investment firm focused on the innovations in molecular medicine reshaping Life Sciences and healthcare. Founded by Eli Casdin in 2011, the firm manages a long-short equity fund and makes private growth equity investments across biotechnology, healthcare, and synthetic biology.
61% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-b (40% of deals). Average disclosed round size is $100.7M (across 166 rounds with reported amounts).
Portfolio
128
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
Bernie Cooney
Senior Managing Director
Shaun Rodriguez, PhD
Director of Life Science Research
Suzanne Angell
Director of Therapeutics Research
Gary Zhou
Research & Marketing Business Analyst
Justin Harris
Senior Quantitative Analyst
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 City Therapeutics | Series B | $99.5M | Jun 2026 |
 Apella Technology | Series B | $80M | Jan 2026 |
 Serapha Bio | Series A | $138M | Jan 2026 |
 Treeline Biosciences | Series A | — | Sep 2025 |
 Thyme Care | Series D | $22M | Jan 2025 |
 PrognomiQ | Series D | $34M | Nov 2024 |
 TMRW | Series D | $28M | Jul 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Cerevance | Series C | $51M | Apr 2024 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
 Maze Therapeutics | Unknown | $115M | Jan 2024 |
| NnChroma | Unknown | $75M | Jan 2024 |
 Neurogene | Series B | $115M | Jan 2024 |
 Nomic Bio | Series B | $42M | Jan 2024 |
 Nomic Bio | Series B | $42M | Jan 2024 |
| Thyme Care | Series B | $60M | Aug 2023 |
 Orbital Therapeutics | Series A | $270M | Apr 2023 |
 Function Oncology | Series A | $28M | Apr 2023 |
 Flare Therapeutics | Series B | $123M | Mar 2023 |
 Chroma Medicine | Series B | $135M | Mar 2023 |
 Vector BioMed | Seed | — | Jan 2023 |
 Nest Genomics | Seed | $8.5M | Jan 2023 |
 Septerna | Series B | — | Jan 2023 |
 NanoCellect | Unknown | $86M | Jan 2023 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
Top Co-Investors
Last updated: 7 October 2026